List view / Grid view
New research has revealed how cellular senescence – the process in which ageing cells change function – shapes human brain structure from development to old age, improving our understanding of brain ageing and neurodegenerative diseases.
Tau drives PSP, CBD and other neurodegenerative diseases, yet there are still no disease-modifying treatments. Here, Dr Glenn Harris from the Rainwater Charitable Foundation shares how a coordinated funding effort is supporting basic research to understand tau mechanisms, improve detection and progress therapeutic development.
Seattle-based biotech company, Variant Bio, have launched Inference, an AI-powered genomics platform designed to accelerate drug discovery and identify genetically supported targets.
Bigger isn’t always better. In drug discovery, Dr Michael Ritchie argues that the future belongs not to those with the most data, but to those who understand its biological depth.
Analysing complex biologics is one of drug discovery’s biggest challenges. At Genentech, Rachel Shi is developing MS workflows that deliver clearer answers, faster.
From precision proteomics to AI-powered immune profiling, next-generation laboratory technologies are changing how new therapies are discovered and developed. Here are four innovations set to shape the lab of the future - and the future of drug discovery.
Can a cholesterol enzyme help treat an untreatable liver disease? Esperion’s ACLY programme is using multiomic and preclinical data to evaluate its potential in primary sclerosing cholangitis.
What role could large language models and AI agents play in drug safety? In Part 3, Layla Hosseini-Gerami of Ignota Labs discusses how emerging technologies might make toxicity analysis faster, more accessible and part of the drug discovery workflow from day one.
Researchers in Brazil and Poland have developed an AI-powered tool that predicts cancer aggressiveness by analysing protein expression - offering new insights into tumour behaviour.
Think drug discovery is slow? This biotech is moving faster, smarter and deeper – by asking the question that no one else has.
K Navigator, a new AI-powered research co-pilot, is set to transform biomedical science by helping researchers explore complex data and accelerate discoveries.
Capgemini's new AI-powered methodology reduces data requirements by 99 percent and accelerates bioengineering breakthroughs, including improved plastic degradation and faster drug discovery.
MIT's new open-source AI model, Boltz-1, could transform drug discovery by accurately predicting protein structures, offering global access to researchers.
Scientists have decoded the 3D structure of a key enzyme linked to Alzheimer's disease. This breakthrough opens up new possibilities for targeted drug development and better treatment options.
The 2024 Nobel Prize in Chemistry honours AI's transformative impact on protein science, with breakthroughs set to reshape drug development.
